Table 1

Clinicopathological information for the ovarian tumors

Patient no.aClinical stageTumor histologySpecimenChemotherapyPFS (mo)b
O2IIIPDc adenocarcinomaPrimaryCarboplatin, Taxol7
O86IIIcMDPrimaryCarboplatin, Taxol7
O37IVNAPrimaryCarboplatin, docetaxol, epirubicin4
AN2IIIaSP, adenocarcinomaPrimaryTaxol, cisplatin, etoposide, topotecanNAd
20TIIIcSP, adenocarcinomaPrimaryCarboplatin, Taxol4
O99IIISP, PDRelapseCyclophosphamide, melphalan(<8)
O8IIIMalignant granulosa cellRelapseCyclophosphamide, cisplatin, doxorubicin(<6)
O5IIIPD adenocarcinomaRelapseChlorambucil5
O98IIIPDRelapseCyclophosphamide, carboplatin14
12TIIIcSP, adenocarcinomaPrimaryCisplatin, Taxol60
O44IVSP, adenocarcinomaPrimaryCarboplatin, Taxol20
26TIVSP, adenocarcinomaPrimaryCarboplatin, Taxol39
O100IVMDRelapseCarboplatin, treosulfan12
O56IIIcPDPrimaryCarboplatin, docetaxol, epirubicin16
AN3IIIcSerous, adenocarcinomaPrimaryCytoxan, carboplatin(<9)
10TIIIcSP, adenocarcinomaPrimaryCisplatin, Taxol12
1TIIIcSP, adenocarcinomaPrimaryMelphalan(60)
O60IIIcSP, PDPrimaryCarboplatin12
O34IVSPPrimaryCarboplatin15
  • a Grouped together following hierarchical clustering analyses (see text for details).

  • b Where PFS data were unavailable, overall survival times are listed in parentheses.

  • c PD, poorly differentiated; MD, moderately differentiated; SP, serous papillary.

  • d NA, not available.